SELLAS Life Sciences (SLS) Liabilities from Discontinued Operations (2014 - 2017)
SELLAS Life Sciences (SLS) reported Liabilities from Discontinued Operations of 6759000.0 for Q3 2017, up 61.12% year-over-year from 4195000.0 in Q3 2016, and down 22.18% on a QoQ basis from 8685000.0 in Q2 2017.
SELLAS Life Sciences (SLS) has 4 years of Liabilities from Discontinued Operations data on file, last reported at 6759000.0 in Q3 2017.
- Quarterly Liabilities from Discontinued Operations rose 61.12% year-over-year to 6759000.0 in Q3 2017, while the trailing twelve-month figure through Sep 2017 was 6759000.0 (up 61.12% YoY) and the FY2016 annual result came in at 6059000.0, up 2.26% from the prior year.
- Liabilities from Discontinued Operations fell to 6759000.0 in Q3 2017 per SLS's latest filing, from 8685000.0 in the prior quarter.
- Across five years, Liabilities from Discontinued Operations topped out at 10045000.0 in Q1 2017 and bottomed at 3727000.0 in Q2 2016.
- The 4-year median for Liabilities from Discontinued Operations is 6409000.0 (2016), against an average of 6474800.0.
- The widest annual swing landed in 2016, when Liabilities from Discontinued Operations sank 45.5%; it then surged 133.03% in 2017.
- Tracing SLS's Liabilities from Discontinued Operations over 4 years: stood at 7169000.0 in 2014, then declined by 17.35% to 5925000.0 in 2015, then gained by 2.26% to 6059000.0 in 2016, then climbed by 11.55% to 6759000.0 in 2017.
- Per Business Quant, the three latest SLS Liabilities from Discontinued Operations figures stand at 6759000.0 (Q3 2017), 8685000.0 (Q2 2017), and 10045000.0 (Q1 2017).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 6.76 Mn |
| Sep 30, 2017 | 6.76 Mn |
| Jun 30, 2017 | 8.69 Mn |
| Jun 30, 2017 | 8.69 Mn |
| Mar 31, 2017 | 10.05 Mn |
| Mar 31, 2017 | 10.05 Mn |
| Dec 31, 2016 | 6.06 Mn |
| Dec 31, 2016 | 6.06 Mn |
| Sep 30, 2016 | 4.20 Mn |
| Sep 30, 2016 | 4.20 Mn |
| Jun 30, 2016 | 3.73 Mn |
| Jun 30, 2016 | 3.73 Mn |
| Mar 31, 2016 | 4.49 Mn |
| Mar 31, 2016 | 4.49 Mn |
| Dec 31, 2015 | 5.93 Mn |
| Dec 31, 2015 | 5.93 Mn |
| Sep 30, 2015 | 7.70 Mn |
| Sep 30, 2015 | 7.70 Mn |
| Dec 31, 2014 | 7.17 Mn |
| Dec 31, 2014 | 7.17 Mn |